TMCnet News
Sicel wins FDA clearance for DVS-HFT wireless sensorMar 10, 2009 (Datamonitor via COMTEX) -- Sicel Technologies, a developer of wireless implantable sensors, has received clearance from the FDA to begin marketing DVS-HFT, the next-generation of the company's original dose verification system wireless implantable dosimeter that remains the only device to measure actual radiation dose at the tumor site for use in treating breast and prostate cancer patients undergoing external beam radiation therapy. According to the company, the medical device expands its portfolio, because the DVS-HFT dosimeter is specifically calibrated for use with radiation therapy protocols that give patients higher single doses of radiation over a shorter period of time compared to conventional radiation therapy. Recent changes by the Centers for Medicaid & Medicare Services (CMS) in the 2009 Hospital Outpatient reimbursement policy for Medicare patients will make dose verification system (DVS) accessible to more patients undergoing radiation therapy treatment in hospital outpatient facilities. The change, effective January 1, 2009 significantly increases reimbursement to facilities implanting the sensors, the company said. Michael Riddle, president and CEO of Sicel, said: "We are very pleased that CMS has acknowledged the importance of breakthrough technologies like DVS in cancer treatment and we continue to work with professional organizations like American Society for Therapeutic Radiology and Oncology, The American Association of Physicists in Medicine, and the AUA to ensure that all patients have access to innovative treatment options." http://www.datamonitor.com Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon |